NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Boehringer Ingellheim back to previous page show list

Boehringer Ingellheim

»
address: Boehringer Ingelheim GmbH
Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany
contact: Phone +49/6132/77 0
Fax +49/6132/72 0
key person: Dr Alessandro Banchi
Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Marketing and Sales.

Dr Andreas Barner
Vice-Chairman of the Board of Managing Directors and Head of Corporate Board D

trunover in millions USD: 13218
R & D turnover in millions USD: 1968
NET profit: 2161
year of financial results: 2006
employees: 38428

active in China: YES
partner in China: Boehringer Ingelheim
International Trading Co.,Ltd.
22F, No. 138 Pudong Avenue
Shanghai, 200120
P.R. China

Boehringer Ingelheim
Shanghai Pharmaceuticals Co., Ltd.
22F, No. 138 Pudong Avenue

SFDA approved: NO

Approvals:
GLP: NO
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and more than 37,000 employees. Since it was founded in 1885, the privately-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
 
They are a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life.Their business consists of Prescription Medicines, Consumer Health Care and Animal Health. Activities grouped under Industrial Customer, include Pharma Chemicals and Biopharmaceuticals.
 
Boehringer Ingelheim set up its China branch office in March 1994. A year later, Boehringer Ingelheim International Trade (Shanghai) Co., Ltd. was registered.  In 1998, Shanghai Boehringer Ingelheim Pharmaceuticals Ltd. was established in Shanghai Zhangjiang High-tech park. The total investment amounts to 29 Mio US$ marking the beginning of the company’s continuous investment to China.  The Zhangjiang Plant has introduced state-of-art manufacturing facility with design, equipment, and management standard that are on a par with those in the plants of other countries.  The plant production strictly follows the international GMP standard.  Currently the company has offices in Shanghai, Beijing, Guangzhou, Chengdu with over 500 employees.  

Boehringer Ingelheim’s business in China is organized into three divisions focusing on prescription medicines, consumer healthcare and animal health, covering major markets in the country. The company spares no effort in bringing innovative pharmaceutical products to China market, and as a result, Boehringer Ingelheim has obtained a strong recognition for the excellence of its product pipeline covering therapeutic areas, ranging from respiratory, cardiovascular and central nerve system medicines to anti-AIDS medicines.
 
Business in China:
 
Business (es): Human Pharmaceuticals, Animal Health
 
Number of employees (2006): 578

Net Sales with third parties (2006): 56 million EUR

Best selling Prescription Medicines products (2006):
Mucosolvan® lurenorm® icardis® trovent®Actilyse® 
     
Best selling Consumer Health Care products (2006):Mucosolvan®
 
Best selling Animal Health products (2006):
Ingelvac®Aujeszky, Ingelvac®PRRS, Ingelvac®M.hyo, Ingelvac®AR4, Ingelvac®H
 

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.